Elizabeth R Plimack

21PUBLICATIONS
177CO-AUTHORS
Molecular targetsPredictive and prognostic markersWomen's studies (incl. girls' studies)Cancer therapy (excl. chemotherapy and radiation therapy)Solid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Sep 11, 2025
End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer.

Andrea Necchi, Matthew D Galsky, Nazli Dizman

|Aug 01, 2025
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial.

Brian I Rini, Elizabeth R Plimack, Viktor Stus

|Apr 10, 2025
Gender Disparities in Citations and Altmetric Attention Score in Oncology.

Rebecca A Campbell, Emma Helstrom, Lauren Chew

|Feb 24, 2025
Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma.

Miya B Hugaboom, Lena V Wirth, Kelly Street

|Dec 16, 2024
Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).

Daniel M Geynisman, Philip H Abbosh, Eric Ross

|Aug 16, 2024
Identification and Validation of Prognostic Model for Tumor Microenvironment-Associated Genes in Bladder Cancer Based on Single-Cell RNA Sequencing Data Sets.

Imran Safder, Henkel Valentine, Nicole Uzzo

Pageof 4

Frequent Collaborators

5 joint publications

Philip H Abbosh

5 joint publications

Daniel M Geynisman

5 joint publications

Matthew Zibelman

4 joint publications

Toni K Choueiri